INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
INmune Bio Inc. (NASDAQ: INMB) has published a landmark paper in the Journal for ImmunoTherapy of Cancer, detailing the biology of their Natural Killer cancer immunotherapy, INKmune™. The study demonstrates that memory-like natural killer (mlNK) cells, generated by either cytokine or INKmune™ priming, show increased cytotoxicity against multiple tumor types. Notably, mlNK cells from cancer patients are as potent as those from healthy volunteers, supporting INKmune's in vivo treatment approach.
The research provides insights into NK cell memory mechanisms, potentially leading to innovative treatments for hematological malignancies and solid tumors. INKmune™ priming increases proteins that protect NK cells in the tumor microenvironment, which is promising for their ongoing clinical trial in metastatic castration-resistant prostate cancer. The study also demonstrates in vivo generation of mlNK cells and their enhanced metabolic function, suggesting improved performance in the tumor microenvironment.
INmune Bio Inc. (NASDAQ: INMB) ha pubblicato un articolo fondamentale nel Journal for ImmunoTherapy of Cancer, dettagliando la biologia della loro immunoterapia contro il cancro Natural Killer, INKmune™. Lo studio dimostra che le cellule Natural Killer simili a quelle della memoria (mlNK), generate da priming con citochina o INKmune™, mostrano un'incrementata citotossicità contro diversi tipi di tumori. È importante notare che le cellule mlNK dei pazienti oncologici sono potenti tanto quanto quelle dei volontari sani, a sostegno dell'approccio terapeutico in vivo di INKmune.
La ricerca fornisce approfondimenti sui meccanismi di memoria delle cellule NK, potenzialmente portando a trattamenti innovativi per le neoplasie ematologiche e i tumori solidi. Il priming con INKmune™ aumenta le proteine che proteggono le cellule NK nell'ambiente tumorale, il che è promettente per il loro studio clinico in corso nel carcinoma prostatico metastatico resistente alla castrazione. Lo studio dimostra anche la generazione in vivo di cellule mlNK e la loro funzione metabolica potenziata, suggerendo prestazioni migliorate nell'ambiente tumorale.
INmune Bio Inc. (NASDAQ: INMB) ha publicado un artículo fundamental en el Journal for ImmunoTherapy of Cancer, detallando la biología de su inmunoterapia contra el cáncer Natural Killer, INKmune™. El estudio demuestra que las células naturales asesinas similares a la memoria (mlNK), generadas ya sea por citoquinas o priming con INKmune™, muestran una citotoxicidad aumentada contra múltiples tipos de tumores. Notablemente, las células mlNK de pacientes con cáncer son tan potentes como las de voluntarios sanos, apoyando el enfoque de tratamiento in vivo de INKmune.
La investigación proporciona información sobre los mecanismos de memoria de las células NK, lo que podría llevar a tratamientos innovadores para malignidades hematológicas y tumores sólidos. El priming con INKmune™ aumenta las proteínas que protegen las células NK en el microambiente tumoral, lo cual es prometedor para su ensayo clínico en cáncer prostático metastásico resistente a la castración. El estudio también demuestra la generación in vivo de células mlNK y su función metabólica mejorada, sugiriendo un rendimiento superior en el microambiente tumoral.
INmune Bio Inc. (NASDAQ: INMB)는 Journal for ImmunoTherapy of Cancer에 그들의 자연 살해(Natural Killer) 암 면역 요법인 INKmune™의 생물학을 자세히 설명한 기념비적인 논문을 발표했습니다. 연구에 따르면, 사이토카인이나 INKmune™ 프라이밍으로 생성된 기억 유사 자연 살해 세포(mlNK)는 여러 종양 유형에 대한 세포 독성이 증가하는 것으로 나타났습니다. 특히, 암 환자의 mlNK 세포는 건강한 자원봉사자의 세포만큼 강력하여 INKmune의 체내 치료 접근법을 지지합니다.
이 연구는 NK 세포의 기억 메커니즘에 대한 통찰력을 제공하여 혈액암 및 고형 종양에 대한 혁신적인 치료법으로 이어질 가능성이 있습니다. INKmune™ 프라이밍은 종양 미세환경에서 NK 세포를 보호하는 단백질을 증가시켜 전이성 거세 저항성 전립선 암에 대한 진행 중인 임상 시험이 유망합니다. 이 연구는 또한 mlNK 세포의 체내 생성을 보여주며, 이들의 대사 기능 향상을 나타내어 종양 미세환경에서의 성능이 개선될 수 있음을 시사합니다.
INmune Bio Inc. (NASDAQ: INMB) a publié un article marquant dans le Journal for ImmunoTherapy of Cancer, détaillant la biologie de leur immunothérapie anticancéreuse à base de cellules tueuses naturelles, INKmune™. L'étude démontre que les cellules tueuses naturelles semblables à la mémoire (mlNK), générées par une priming avec des cytokines ou avec INKmune™, montrent une cytotoxicité accrue contre plusieurs types de tumeurs. Notamment, les cellules mlNK des patients atteints de cancer sont aussi puissantes que celles des volontaires sains, soutenant l'approche de traitement in vivo d'INKmune.
La recherche fournit des aperçus sur les mécanismes de mémoire des cellules NK, pouvant mener à des traitements innovants pour les malignités hématologiques et les tumeurs solides. La priming avec INKmune™ augmente les protéines qui protègent les cellules NK dans le microenvironnement tumoral, ce qui est prometteur pour leur essai clinique en cancer de la prostate métastatique résistant à la castration. L'étude démontre également la génération in vivo de cellules mlNK et leur fonction métabolique améliorée, suggérant une performance accrue dans le microenvironnement tumoral.
INmune Bio Inc. (NASDAQ: INMB) hat ein bahnbrechendes Papier im Journal for ImmunoTherapy of Cancer veröffentlicht, das die Biologie ihrer natürlichen Killer-Immuntherapie gegen Krebs, INKmune™, detailliert. Die Studie zeigt, dass gedächtnisähnliche natürliche Killerzellen (mlNK), die entweder durch Zytokine oder durch INKmune™-Prägung erzeugt wurden, eine erhöhte Zytotoxizität gegen mehrere Tumorarten aufweisen. Besonders bemerkenswert ist, dass mlNK-Zellen von Krebspatienten ebenso potent sind wie die von gesunden Freiwilligen, was den in vivo-Behandlungsansatz von INKmune unterstützt.
Die Forschung liefert Einblicke in die Gedächtnismechanismen der NK-Zellen und könnte zu innovativen Behandlungen für hämatologische Malignitäten und solide Tumoren führen. Die Prägung mit INKmune™ erhöht Proteine, die NK-Zellen im Tumormikroenvironment schützen, was vielversprechend für ihre laufende klinische Studie bei metastasiertem kastrationsresistentem Prostatakrebs ist. Die Studie zeigt auch die in vivo-Generierung von mlNK-Zellen und deren verbesserte metabolische Funktion, was auf eine verbesserte Leistung im Tumormikroenvironment hindeutet.
- Publication of research in a high-impact, peer-reviewed scientific journal
- INKmune™ shows increased cytotoxicity against multiple tumor types
- mlNK cells from cancer patients are as potent as those from healthy volunteers
- First demonstration of in vivo generation of mlNK cells
- Enhanced metabolic function of NK cells primed by INKmune™
- Ongoing clinical trial for metastatic castration-resistant prostate cancer
- None.
Insights
The recent publication by INmune Bio on their INKmune™ therapy is a significant milestone in cancer immunotherapy. This study shows that memory-like natural killer (mlNK) cells, primed by INKmune, exhibit enhanced cytotoxicity against tumors. What stands out is the demonstration that mlNK cells from cancer patients are as potent as those from healthy volunteers. This is important because it supports the potential real-world applicability of their treatment. Moreover, the ability of INKmune to prime mlNK cells in vivo, an achievement not possible with traditional cytokine cocktails, represents a significant advantage. From a research perspective, this validates INKmune’s unique mechanism of action, offering a promising avenue for combating various malignancies, including hematological and solid tumors.
The findings from INmune Bio's study are promising for the field of oncology. The memory-like NK cells' enhanced ability to kill tumor cells, particularly in a hostile tumor microenvironment, could revolutionize treatment protocols. The emphasis on improved metabolic function is especially noteworthy as metabolic impairment is a common hurdle in effective NK cell responses. The in vivo generation of these potent mlNK cells marks a significant advancement, validating the clinical potential of INKmune. If these findings translate successfully in ongoing clinical trials for metastatic castration-resistant prostate cancer, it may open up new therapeutic options for patients who currently have limited treatment choices.
From a financial perspective, the publication of this research in a high-impact journal adds credibility to INmune Bio’s technology and could positively influence investor sentiment. The potential of INKmune to enhance NK cell function in cancer patients could translate into successful clinical outcomes, driving the company's valuation higher. However, it’s important to monitor the preliminary results from the ongoing clinical trial set to be released later this year. Positive data could lead to a significant appreciation in stock price as it cements clinical efficacy; conversely, any negative results might impact investor confidence. Investors should also consider the competitive landscape and how INKmune’s unique benefits compare to other emerging therapies in the immunotherapy space.
Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics
BOCA RATON, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced the publication of our landmark paper in Journal Immunotherapy of Cancer co-authored by Mark Lowdell, PhD, INmune’s Chief Scientific Officer, titled, “ Proteomic and phenotypic characteristics of memory-like Natural Killer cells for cancer immunotherapy.” Link to paper: https://jitc.bmj.com/content/12/7/e008717
The study demonstrates that memory-like natural killer (mlNK) cells, generated by either cytokine or INKmuneTM priming, show increased cytotoxicity against multiple tumor types, offering promising potential for cancer immunotherapy. Importantly, while most studies are conducted on NK cells from healthy volunteers, this study demonstrated that mlNK from cancer patients are equally as potent as those generated from healthy volunteers further supporting INKmune’s in vivo treatment methodology. The research also provides new insights into the metabolic and physiological mechanisms underlying NK cell memory, paving the way for innovative treatments in both hematological malignancies and solid tumors.
“The study of NK cell biology is evolving rapidly. This is the first study to identify the unique characteristics of tumor killing memory like NK cells and points to ways to enhance their potential further for cancer immunotherapy,” said Mark Lowdell PhD, CSO of INmune Bio and inventor of INKmuneTM. “INKmuneTM priming increases proteins which protect NK cells in the hostile tumor microenvironment which is exciting for our ongoing clinical trial in metastatic castration-resistant prostate cancer. This research study, led by INmune Bio, was a commercial and academic collaboration over several years and we are delighted to see it published in a high impact, peer-reviewed scientific journal.”
Most significantly, this study is the first to demonstrate in vivo generation of mlNK cells; something which cannot be done with the cytokine cocktail used in vitro. The researchers successfully showed that these mlNK cells, primed by INKmuneTM, can be found in patients after treatment, a critical step in proving our claimed mechanism of action.
Additionally, the paper highlights the enhanced metabolic function of the NK cells primed by INKmuneTM, predicting improved performance in the tumor microenvironment (TME). “This research is particularly noteworthy as NK cell dysfunction in the TME is often due to impaired metabolism,” stated RJ Tesi, INmune’s CEO. “The findings suggest that INKmune priming can overcome these metabolic barriers, leading to more effective NK cell resposes against tumors.”
INmune Bio is currently conducting a trial of INKmuneTM in the treatment of metastatic castration-resistant prostate cancer. Preliminary results from that trial are expected later this year.
About INKmune™
INKmune™ is a pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals to convert the cancer patient’s resting NK cells into tumor killing memory-like NK cells (mlNK cells). INKmune™ treatment converts the patient’s own NK cells into mlNK cells. In patients, INKmune™ primed tumor killing NK cells have persisted for more than 100 days. These cells function in the hypoxic TME because due to upregulated nutrient receptors and mitochondrial survival proteins.
INKmune™ is a patient friendly drug treatment that does not require pre-medication, conditioning or additional cytokine therapy to be given to the patients. INKmune™ is easily transported, stored and delivered to the patient by a simple intravenous infusion as an out-patient. INKmune™ is tumor agnostic; it can be used to treat many types of NK-resistant tumors including leukemia, lymphoma, myeloma, lung, ovarian, breast, renal and nasopharyngeal cancer. INKmune™ is treating patients in an open label Phase I/II trial in metastatic castration-resistant prostate cancer in the US this year.
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Early Alzheimer’s disease and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595 (XPro™), and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss
Chief Financial Officer
(858) 964-3720
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
Investor Contact:
Mike Moyer
Managing Director – LifeSci Advisors
mmoyer@lifesciadvisors.com
FAQ
What is the main finding of INmune Bio's (INMB) recent study on INKmune™?
How does INKmune™ (INMB) differ from other NK cell therapies?
What clinical trial is INmune Bio (INMB) currently conducting with INKmune™?
How does INKmune™ (INMB) potentially overcome NK cell dysfunction in the tumor microenvironment?
